齐拉西酮治疗精神分裂症临床应用指导建议

2021-09-30 中国精神科相关专家小组 中国新药与临床杂志

精神分裂症是一组临床表现复杂、病程迁延的严重损害患者社会功能的致残性脑病, 患者常需要长期药物治疗。

中文标题:

齐拉西酮治疗精神分裂症临床应用指导建议

发布日期:

2021-09-30

简要介绍:

精神分裂症是一组临床表现复杂、病程迁延的严重损害患者社会功能的致残性脑病, 患者常需要长期药物治疗。新型第二代抗精神病药进入临床后, 因能同时有效治疗阳性症状、阴性症状、认知损害和心境症状, 改善社会功能, 已成为一线治疗选择。齐拉西酮作为新型第二代抗精神病药, 在临床使用中具有疗效明确、不良反应相对较少和改善患者功能的特点, 但在临床应用中要求医生在使用方法和治疗学原理方面掌握更为全面的知识和技能。本文重点介绍近年来国内外在齐拉西酮临床应用中的治疗学研究和经验, 结合笔者的观点, 为广大精神科临床医生提供更为合理的用药方法, 进一步改善患者的治疗结局。

相关资料下载:
[AttachmentFileName(sort=1, fileName=齐拉西酮治疗精神分裂症临床应用指导建议.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2d5101c00225032b, title=齐拉西酮治疗精神分裂症临床应用指导建议, enTitle=, guiderFrom=中国新药与临床杂志, authorId=0, author=, summary=精神分裂症是一组临床表现复杂、病程迁延的严重损害患者社会功能的致残性脑病, 患者常需要长期药物治疗。, cover=https://img.medsci.cn/2021112/1635820829787_1608702.jpg, journalId=0, articlesId=null, associationId=812, associationName=中国精神科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Thu Sep 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">精神分裂症是一组临床表现复杂、病程迁延的严重损害患者社会功能的致残性脑病, 患者常需要长期药物治疗。新型第二代抗精神病药进入临床后, 因能同时有效治疗阳性症状、阴性症状、认知损害和心境症状, 改善社会功能, 已成为一线治疗选择。齐拉西酮作为新型第二代抗精神病药, 在临床使用中具有疗效明确、不良反应相对较少和改善患者功能的特点, 但在临床应用中要求医生在使用方法和治疗学原理方面掌握更为全面的知识和技能。本文重点介绍近年来国内外在齐拉西酮临床应用中的治疗学研究和经验, 结合笔者的观点, 为广大精神科临床医生提供更为合理的用药方法, 进一步改善患者的治疗结局。</span></p>, tagList=[TagDto(tagId=1344, tagName=精神分裂症), TagDto(tagId=82811, tagName=齐拉西酮)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=82811, guiderKeyword=齐拉西酮, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2121, appHits=62, showAppHits=0, pcHits=486, showPcHits=2059, likes=1, shares=5, comments=6, approvalStatus=1, publishedTime=Tue Nov 02 11:14:32 CST 2021, publishedTimeString=2021-09-30, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Tue Nov 02 10:43:43 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 11:07:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=齐拉西酮治疗精神分裂症临床应用指导建议.pdf)])
齐拉西酮治疗精神分裂症临床应用指导建议.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077438, encodeId=930610e743809, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=454b5463066, createdName=魏一, createdTime=Mon Dec 06 18:41:20 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068344, encodeId=a9701068344f1, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Tue Nov 09 00:07:51 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066218, encodeId=70501066218a3, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 02 13:21:58 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-12-06 魏一

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077438, encodeId=930610e743809, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=454b5463066, createdName=魏一, createdTime=Mon Dec 06 18:41:20 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068344, encodeId=a9701068344f1, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Tue Nov 09 00:07:51 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066218, encodeId=70501066218a3, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 02 13:21:58 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-09 ms3000001712111982

    喜欢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077438, encodeId=930610e743809, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=454b5463066, createdName=魏一, createdTime=Mon Dec 06 18:41:20 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068344, encodeId=a9701068344f1, content=喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ec5699921, createdName=ms3000001712111982, createdTime=Tue Nov 09 00:07:51 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066218, encodeId=70501066218a3, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 02 13:21:58 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-02 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0